专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012151058A1 (20S)-24-(P-TOLUENESULFONYLOXY)-25,26,27-TRINORVITAMIN D3 ANALOGS AND THEIR USES 审中-公开
标题翻译：（20S）-24-（对 - 戊二烯氧基）-25,26,27-三硝基维生素D3类似物及其用途
公开(公告)号：WO2012151058A1
公开(公告)日：2012-11-08
申请号：PCT/US2012/034266
申请日：2012-04-19
申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION , DELUCA, Hector, F. , CLAGETT-DAME, Margaret , PLUM, Lori, A. , BARYCKI, Rafal
发明人： DELUCA, Hector, F. , CLAGETT-DAME, Margaret , PLUM, Lori, A. , BARYCKI, Rafal
IPC分类号： A61K31/593 , C07C309/73 , A61P35/00
CPC分类号： C07C401/00 , C07C2601/14 , C07C2602/24
摘要： This invention discloses (20S)-24-( p -toluenesulfonyloxy)-25,26,27-trinorvitarnin D 3 analogs, and especially (20S)-25,26,27-trinor-24-|( p -methyiphenylsulfonate)-vitamin D 3 , its biological activities, and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation of HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate, bone or ovarian cancer cells. This compound thus causes specific cell death in the absence of changes in calcium levels and without general toxicity in an animal. Therefore it might serve as a useful therapy for treatment of some forms of cancer, such as leukemia and lung cancer.
摘要翻译：本发明公开了（20S）-24-（对甲苯磺酰氧基）-25,26,27-三硝维生素D3类似物，特别是（20S）-25,26,27-三硝基-24-（对甲基亚苯基磺酸酯） - 维生素D3 ，其生物活性及其制药用途。该化合物显示相对较少的钙血活性，并且不促进HL-60白血病细胞的细胞分化，而是杀死细胞。这种细胞死亡活动也在小细胞肺癌中发现，但在前列腺，骨或卵巢癌细胞中也没有。因此，该化合物在没有钙水平的变化并且在动物中没有一般毒性的情况下引起特异性细胞死亡。因此，它可能是治疗某些形式的癌症（如白血病和肺癌）的有用治疗方法。

2. 发明申请

WO2011119610A2 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3 审中-公开
标题翻译：（20S）-2-甲基-19-异-22-二甲基-1a，25-二羟基维生素D3和（20R）-2-甲基-19-异-22-二甲基-1,1,25-羟基维生素D3
公开(公告)号：WO2011119610A2
公开(公告)日：2011-09-29
申请号：PCT/US2011/029432
申请日：2011-03-22
申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION , DELUCA, Hector F. , FLORES, Agnieszka , GRZYWACZ, Pawel , PLUM, Lori A. , CLAGETT-DAME, Margaret
发明人： DELUCA, Hector F. , FLORES, Agnieszka , GRZYWACZ, Pawel , PLUM, Lori A. , CLAGETT-DAME, Margaret
IPC分类号： C07C401/00 , C07F7/18 , A61K31/59 , A61P19/08 , A61P17/06 , A61P37/00
CPC分类号： C07F7/1856 , C07C401/00 , C07C2601/14 , C07C2602/24 , Y02P20/55
摘要： Compounds of formula I are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
摘要翻译：提供式I化合物，其中X 1，X 2和X 3独立地选自H或羟基保护基。这样的化合物可用于制备药物组合物，并且可用于治疗各种生物学条件。

3. 发明申请

WO2011041596A2 19-NOR-VITAMIN D ANALOGS WITH 1,2-OR 3,2-CYCLOPENTENE RING 审中-公开
标题翻译：具有1,2-或3,2-环戊烯环的19-NOR-维生素D类似物
公开(公告)号：WO2011041596A2
公开(公告)日：2011-04-07
申请号：PCT/US2010050984
申请日：2010-09-30
申请人： WISCONSIN ALUMNI RES FOUND , DELUCA HECTOR F , GLEBOCKA AGNIESZKA , PLUM LORI A , CLAGETT-DAME MARGARET , SICINSKI RAFAL R
发明人： DELUCA HECTOR F , GLEBOCKA AGNIESZKA , PLUM LORI A , CLAGETT-DAME MARGARET , SICINSKI RAFAL R
IPC分类号： A61K31/59 , A61P35/00 , A61P35/02 , C07C35/23 , C07C49/633 , C07F7/08
CPC分类号： C07C401/00
摘要： 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.
摘要翻译：描述了具有连接碳1和碳2的另外的环戊烯环或连接类似物的A环的碳3和碳-2的19-去甲 - 维生素D类似物及其药物用途。这些化合物表现出选择性的体外活性，使其成为治疗或预防某些类型的癌症，特别是白血病，结肠癌，乳腺癌，皮肤癌或前列腺癌的治疗剂。

4. 发明申请

WO2010006162A3 2-METHYLENE-(20E)-20(22)-DEHYDRO-19-NOR-VITAMIN D ANALOGS 审中-公开
标题翻译： 2-甲基 - （20E）-20（22） - 脱氢-19-异维生素D类似物
公开(公告)号：WO2010006162A3
公开(公告)日：2010-05-20
申请号：PCT/US2009050094
申请日：2009-07-09
申请人： WISCONSIN ALUMNI RES FOUND , DELUCA HECTOR E , TADI PADMAJA BULLI , PLUM LORI A , CLAGETT-DAME MARGARET
发明人： DELUCA HECTOR E , TADI PADMAJA BULLI , PLUM LORI A , CLAGETT-DAME MARGARET
IPC分类号： C07C401/00 , A61K31/593 , A61P3/04 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/02
CPC分类号： C07C401/00
摘要： This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-la,25- dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone la,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
摘要翻译：本发明公开了2-亚甲基 - （20E）-20（22） - 脱氢-19-去甲维生素D类似物，特别是2-亚甲基 - （20E）-20（22） - 脱氢-19-去甲酰基，25 - 二羟基维生素D3及其制药用途。该化合物显示相对较高的转录活性以及阻止未分化细胞增殖并诱导其分化为单核细胞的显着活性，从而证明其用作抗癌剂并用于治疗皮肤疾病如牛皮癣以及皮肤病症如皱纹，皮肤松弛，皮肤干燥和皮脂分泌不足。与天然激素la，25-二羟基维生素D 3相比，该化合物在骨钙动员和体内肠钙运输活性方面的体内活性也较低，因此可用于治疗人体以及肾脏中的自身免疫性疾病或炎性疾病性骨病。该化合物也可用于治疗或预防肥胖症。

5. 发明申请

WO2010006172A3 2-METHYLENE-20(21)-DEHYDRO-19-NOR-VITAMIN D ANALOGS 审中-公开
公开(公告)号：WO2010006172A3
公开(公告)日：2010-01-14
申请号：PCT/US2009/050110
申请日：2009-07-09
申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION , DELUCA, Hector, F. , TADI, Bulli, Padmaja , PLUM, Lori, A. , CLAGETT-DAME, Margaret
发明人： DELUCA, Hector, F. , TADI, Bulli, Padmaja , PLUM, Lori, A. , CLAGETT-DAME, Margaret
IPC分类号： C07C401/00 , A61K31/593 , A61P3/04 , A61P17/00 , A61P17/06 , A61P29/00 , A61P35/00 , A61P37/02
摘要： This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D 3 , and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

6. 发明申请

WO2009086440A1 2-METHYLENE-20-METHYL-19,24,25,26,27-PENTANOR-VITAMIN D ANALOGS 审中-公开
标题翻译： 2-甲基-20-甲基-19,24,25,26,27-戊烷维生素D类似物
公开(公告)号：WO2009086440A1
公开(公告)日：2009-07-09
申请号：PCT/US2008/088276
申请日：2008-12-24
申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION , DELUCA, Hector, F. , CLAGETT-DAME, Margaret , PLUM, Lori, A. , GLEBOCKA, Agnieszka , SICINSKI, Rafal, R.
发明人： DELUCA, Hector, F. , CLAGETT-DAME, Margaret , PLUM, Lori, A. , GLEBOCKA, Agnieszka , SICINSKI, Rafal, R.
IPC分类号： C07C401/00 , A61K31/593 , A61P3/14 , A61P17/06 , A61P35/02 , A61P37/06 , A61P19/02
CPC分类号： C07C401/00
摘要： This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor- vitamin D analogs, and specifically 2-methylene-20-methyl-lα-hydroxy-19,24,25,26,27-pentanor- vitamin D 3 , and pharmaceutical uses therefore. This compound exhibits activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
摘要翻译：本发明公开了2-亚甲基-20-甲基-19,24,25,26,27-戊醇维生素D类似物，特别是2-亚甲基-20-甲基-1a-羟基-19,24,25,26,27 维生素D3和维生素D3，因此也是药用。该化合物显示出阻止未分化细胞增殖并诱导其分化为单核细胞的活性，从而证明其用作抗癌剂并用于治疗皮肤疾病如牛皮癣以及皮肤病症如皱纹，松弛皮肤，干燥皮肤和皮脂分泌不足。该化合物也具有很少（如果有的话）钙活性，因此可用于治疗人体中的自身免疫性疾病或炎性疾病以及肾性骨营养不良。该化合物也可用于治疗或预防肥胖症。

7. 发明申请

WO2008083370A3 COMPOUNDS, COMPOSTIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINSTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A REYINOID 审中-公开
标题翻译：化合物，组合物，使用方法和使用方法通过给予含有或不含有REYINOID的19-NOR含维生素D类似物进行口服治疗和其他皮肤病症
公开(公告)号：WO2008083370A3
公开(公告)日：2009-06-18
申请号：PCT/US2007089193
申请日：2007-12-31
申请人： WISCONSIN ALUMNI RES FOUND , CLAGETT-DAME MARGARET , DELUCA HECTOR F , NIEVES NIRCA J , PLUM LORI A , KAISER MARY E , BARYCKI RAFAL
发明人： CLAGETT-DAME MARGARET , DELUCA HECTOR F , NIEVES NIRCA J , PLUM LORI A , KAISER MARY E , BARYCKI RAFAL
IPC分类号： A61K9/00 , A61K9/48 , A61K31/203 , A61K31/59 , A61K47/10 , A61K47/44
CPC分类号： A61K31/59 , A61K8/67 , A61K9/0014 , A61K9/0053 , A61K9/0095 , A61K31/203 , A61K47/10 , A61K47/44 , A61K2800/92 , A61Q19/00 , A61Q19/004 , A61Q19/08
摘要： Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-la-hydroxy-bishomopregnacalciferol, 19-nor- 26,27-dimethylene-20(S)-2-methylene-la,25-dihydroxyvitamin D3, 2-methylene-la,25- dihydroxy-( 17E)- 17(20)-dehydro- 19-nor-vitamin D3, 2-methylene- 19-nor-(24R)- 1 a,25- dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-la,25-dihydroxyvitamin D3, 2- methylene- 19-nor- 1 a-hydroxy-pregnacalciferol, 1 a-hydroxy-2-methylene- 19-nor- homopregnacalciferol, (20R)- 1 a-hydroxy-2-methylene- 19-nor-bishomopregnacalciferol, 2- methylene- 19-nor-(20S)- 1 a-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro- 1 a-hydroxy- 19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23 -difluoro- 1 a-hydroxy- 19-nor-bishomopregnancalciferol, (2 -(3 'hydroxypropyl- 1 ',2 ' -idene)- 19,23,24-trinor-(20S)- la-hydroxyvitamin D3, 2-methylene- 18, 19-dinor-(20S)-la,25-dihydroxyvitamin D3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof. Compounds that activate retinoic acid receptors, such as retinoyls and retinoyl esters, include 13-cw-retmoic acid, all-trafls-retinoic acid, (2E,4E,6Z,8E)-3,7-dimethyl-9- (2,6,6-trimethyl-l-cyclohexeneyl)nona-2,4,6,8-tetraenoic acid, 9-(4-methoxy-2,3,6-trimethyl- phenyl)-3,7-dimethyl-nona-2,4,6, 8-tetraenoic acid, 6- [3 -( 1 -adamantyl)-4-methox yphenyl] -2- napthoic acid, 4-[l-(3,5,5,8,8-pentamethyl-tetralin-2-yl)ethenyl]benzoic acid, retinobenzoic acid, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate, retinoyl t- butyrate, retinoyl pinacol, retinoyl cholesterol, an isomer thereof, a prodrug thereof for oral compositions, an ester thereof, a salt thereof, and/or, a solute thereof. Combinations of such active ingredients demonstrate synergistic efficacy.
摘要翻译：用于治疗各种皮肤病，包括痤疮，牛皮癣，鱼鳞病，光老化，光损伤皮肤和皮肤癌的口服和局部药物组合物，试剂盒和治疗方法。作为活性药物成分的示例性维生素D类似物包括2-亚甲基-19-去甲基（S）-la-羟基 - 双代孕代孕甾醇，19-降-26,27-二亚甲基-20（S）-2-亚甲基-1a，25 - 二羟基维生素D3，2-亚甲基-1a，25-二羟基 - （17E）-17（20） - 脱氢-19-去甲维生素D3，2-亚甲基-19-去甲 - （24R）-1a，25-二羟基维生素 D2，2-亚甲基 - （20R，25S）-19,26-二氢-17,25-二羟基维生素D3，2-亚甲基-19-去甲-α-羟基 - 孕代孕甾醇，1α-羟基-2-亚甲基-19 （20R）-1α-羟基-2-亚甲基-19-去氧胆钙孕激醇，2-亚甲基-19-去甲 - （20S）-1α-羟基 - 三孕代孕代胆甾醇，2-亚甲基-23,23 （20S）-23,23-二氟-11α-羟基-19-去氧胆钙孕激醇，（2-（3'羟丙基-1'，2-羟基丙基）（20S）-L-羟基维生素D3，2-亚甲基-18,19-二烯 - （20S）-la，25-二羟基维生素D 3，其立体异构体，前体药物的口服组合物，盐和/或其溶质。激活视黄酸受体的化合物，如视黄酰基和视黄酰酯，包括13-cw-retmo酸，全转录维甲酸（2E，4E，6Z，8E）-3,7-二甲基-9-（2， 6,6-三甲基-1-环己烯基）壬-2,4,6,8-四烯酸，9-（4-甲氧基-2,3,6-三甲基 - 苯基）-3,7-二甲基 - 壬-2 ，4,6,8-四烯酸，6- [3-（1-金刚烷基）-4-甲氧基苯基] -2-萘甲酸，4- [1-（3,5,5,8,8-五甲基 - 四氢化萘-2-基）乙烯基]苯甲酸，视黄基苯甲酸，6- [2-（4,4-二甲基二氢苯并噻喃-6-基）乙炔基]吡啶-3-甲酸乙酯，视黄酸叔丁酸酯，视黄酰基频哪醇，视黄酰胆固醇，其异构体，其口服组合物的前药，其酯，其盐和/或其溶质。这些活性成分的组合表现出协同效力。

8. 发明申请

WO2008023278A8 1ALPHA-HYDROXY-2- (3 ' -HYDROXYPROPYLIDENE) -19-N0R- VITAMIN D COMPOUNDS WITH A 1,1-DIMETHYLPROPYL SIDE CHAIN 审中-公开
标题翻译： 1ALPHA-羟基-2-（3'-羟甲基吡啶）-19-N0R-维生素D化合物与1,1-二甲基丙烯酰胺链
公开(公告)号：WO2008023278A8
公开(公告)日：2008-12-31
申请号：PCT/IB2007003643
申请日：2007-04-06
申请人： WISCONSIN ALUMNI RES FOUND , DELUCA HECTOR F , GLEBOCKA ANGIESZKA , SICINSKI RAFAL R , PLUM LORI A , CLAGETT-DAME MARGARET
发明人： DELUCA HECTOR F , GLEBOCKA ANGIESZKA , SICINSKI RAFAL R , PLUM LORI A , CLAGETT-DAME MARGARET
IPC分类号： C07C401/00 , A61K31/59 , A61P3/04 , A61P17/00 , A61P17/06 , A61P29/00 , A61P35/00 , A61P37/06
CPC分类号： C07C401/00 , C07F7/1856
摘要： This invention discloses la-hydroxy-2-(3'-hydroxypropylidene)-19-nor- vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. These compounds may also be used for the treatment or prevention of obesity.
摘要翻译：本发明公开了具有1,1-二甲基丙基侧链的α-羟基-2-（3'-羟基亚丙基）-19-去甲维生素D化合物及其制药用途。这些化合物在阻止未分化细胞的增殖和诱导其分化为单核细胞方面表现出显着的活性，从而证明其用作抗癌剂并用于治疗皮肤疾病如牛皮癣以及皮肤病症如皱纹，松弛皮肤，皮肤干燥，皮脂分泌不足。这些化合物也具有很少（如果有的话）钙活性，因此可用于治疗人类的自身免疫性疾病或炎性疾病以及肾性骨营养不良。这些化合物也可用于治疗或预防肥胖症。

9. 发明申请

WO2007092720A8 VITAMIN D ANALOG: NEL, METHODS AND USES THEREOF 审中-公开
标题翻译：维生素D类似物：NEL，其方法和用途
公开(公告)号：WO2007092720A8
公开(公告)日：2008-08-28
申请号：PCT/US2007061402
申请日：2007-01-31
申请人： WISCONSIN ALUMNI RES FOUND , DELUCA HECTOR F , CHIELLINI GRAZIA , GRZYWACZ PAWEL , PLUM LORI A , CLAGETT-DAME MARGARET
发明人： DELUCA HECTOR F , CHIELLINI GRAZIA , GRZYWACZ PAWEL , PLUM LORI A , CLAGETT-DAME MARGARET
IPC分类号： C07C401/00 , A61K31/59 , A61P13/12 , A61P17/06 , A61P19/00 , A61P35/00
CPC分类号： C07C401/00 , C07F7/1856 , Y02P20/55
摘要： Compounds of formula IA or IB are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups and R 1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to 8 carbon atoms; straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms; straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
摘要翻译：提供式IA或IB的化合物，其中X 1，X 2和X 3独立地选自H或羟基保护基， SUB> 1 选自具有1至8个碳原子的直链或支链烷基; 具有2-8个碳原子的直链或支链烯基; 具有1至8个碳原子的直链或支链羟基取代的烷基; 具有2-8个碳原子的直链和支链羟基取代的烯基。这些化合物用于制备药物组合物，并且可用于治疗各种生物学条件。

10. 发明申请

WO2008035228A3 2- SUBSTITUTED-1ALPHA, 25-DIHYDROXY-19,26,27-TRINOR VITAMIN D ANALOGS AND USES THEREOF 审中-公开
标题翻译： 2-取代的1ALPHA，25-二羟基-19,26,27-三核苷酸维生素D类似物及其用途
公开(公告)号：WO2008035228A3
公开(公告)日：2008-06-05
申请号：PCT/IB2007003919
申请日：2007-04-06
申请人： WISCONSIN ALUMNI RES FOUND , DELUCA HECTOR F , PLUM LORI A , CLAGETT-DAME MARGARET , GRZYWACZ PAWEL K
发明人： DELUCA HECTOR F , PLUM LORI A , CLAGETT-DAME MARGARET , GRZYWACZ PAWEL K
IPC分类号： C07C401/00 , A61K31/59 , A61P5/20 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P35/00
CPC分类号： C07C401/00 , Y02P20/55
摘要： Compounds of Formula (I), (II) or (III) are provided where X 1 , X 2 and X 3 are independently selected from H and hydroxy protecting groups and R 1 and R 2 are independently selected from H or straight or branched chain alkyl groups having from 1 to 8 carbon atoms, straight or branched chain alkenyl groups having from 2 to 8 carbon atoms, straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms, or straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms; and R 3 is independently selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms, straight or branched chain alkenyl groups having from 2 to 8 carbon atoms, straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms, or straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
摘要翻译：提供式（I），（II）或（III）的化合物，其中X 1，X 2和X 3独立地选自 H和羟基保护基，R 1和R 2独立地选自H或具有1至8个碳原子的直链或支链烷基，直链或支链烯基具有2至8个碳原子的基团，具有1至8个碳原子的直链或支链羟基取代的烷基，或具有2至8个碳原子的直链和支链羟基取代的烯基; R 3独立地选自具有1至8个碳原子的直链或支链烷基，具有2至8个碳原子的直链或支链烯基，直链或支链羟基取代的烷基具有1至8个碳原子的基团，或具有2至8个碳原子的直链和支链羟基取代的烯基。这些化合物用于制备药物组合物，并且可用于治疗各种生物学条件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式